Literature DB >> 33886037

Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics.

Rodney M Camire1,2.   

Abstract

Blood coagulation factor X/Xa sits at a pivotal point in the coagulation cascade and has a role in each of the three major pathways (intrinsic, extrinsic and the common pathway). Due to this central position, it is an attractive therapeutic target to either enhance or dampen thrombin generation. In this brief review, I will summarize key developments in the molecular understanding of this critical clotting factor and discuss the molecular basis of FX deficiency, highlight difficulties in expressing recombinant factor X, and detail two factor X variants evaluated clinically.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Coagulation; Factor X; Factor Xa; Protein therapeutic; Recombinant proteins

Mesh:

Substances:

Year:  2021        PMID: 33886037      PMCID: PMC8531165          DOI: 10.1007/s11239-021-02456-w

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   5.221


  65 in total

1.  Bovine factor X1 (Stuart factor). Primary structure of the light chain.

Authors:  D L Enfield; L H Ericsson; K A Walsh; H Neurath; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

Review 2.  Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes.

Authors:  A R Khan; M N James
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

3.  A rapid pro-hemostatic approach to overcome direct oral anticoagulants.

Authors:  Nabil K Thalji; Lacramioara Ivanciu; Robert Davidson; Phyllis A Gimotty; Sriram Krishnaswamy; Rodney M Camire
Journal:  Nat Med       Date:  2016-07-25       Impact factor: 53.440

4.  A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo.

Authors:  A R Giles; K G Mann; M E Nesheim
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

5.  Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide.

Authors:  R M Camire; P J Larson; D W Stafford; K A High
Journal:  Biochemistry       Date:  2000-11-21       Impact factor: 3.162

6.  Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Authors:  Alexander T Cohen; Theodore E Spiro; Harry R Büller; Lloyd Haskell; Dayi Hu; Russell Hull; Alexandre Mebazaa; Geno Merli; Sebastian Schellong; Alex C Spyropoulos; Victor Tapson
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

7.  The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-trypsinogen.

Authors:  W Bode
Journal:  J Mol Biol       Date:  1979-02-05       Impact factor: 5.469

8.  Characterization of a cDNA coding for human factor X.

Authors:  S P Leytus; D W Chung; W Kisiel; K Kurachi; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

9.  Molecular characterization of human factor XSan Antonio.

Authors:  S V Reddy; Z Q Zhou; K J Rao; J P Scott; H Watzke; K A High; P Jagadeeswaran
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

10.  The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.

Authors:  W Bode; I Mayr; U Baumann; R Huber; S R Stone; J Hofsteenge
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.